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Objective: Attention deficit hyperactivity disorder (ADHD) is a common, highly heritable psychiatric disorder. Because of its multifactorial etiology, 
however, identifying the genes involved has been difficult. The authors followed up on recent findings suggesting that rare copy num ber variants (CNVs) 
may be important for ADHD etiology.  
Method: The authors performed a genome-wide analysis of large, rare CNVs (<1% population frequency) in children with ADHD (N=896) and comparison 
subjects (N=2,455) from the IMAGE II Consortium .  
Results:The authors observed 1,562 individually rare CNVs >100 kb in size, which segregated into 912 independent loci. Overall, the rate of rare CNVs >100 
kb was  
1.15 times higher in ADHD case subjects relative to comparison subjects, with duplications spanning known genes show ing a 1.2-fold enrichment. In 
accordance with a previous study, rare CNVs >500 kb showed the greatest enrichment (1.28fold). CNVs identified in ADHD case subjects were significantly 
enriched for loci implicated in autism and in schizophrenia. Duplications spanning the CHRNA7 gene at chromosome 15q13.3 were associated with ADHD 
in single-locus analysis. This finding was consistently replicated in an additional 2,242 ADHD case subjects and 8,552 comparison subjects from four 
independent cohorts from the United Kingdom, the United States, and Canada. Presence of the duplication at 15q13.3 appeared to be associated with 
comorbid conduct disorder.  
Conclusions: These findings support the enrichment of large, rare CNVs in ADHD and implicate duplications at 15q13.3 as a novel risk factor for ADHD. 
With a frequency of 0.6% in the populations investigated and a relatively large effect size (odds ratio=2.22, 95% confidence interval=1.5–3.6), this locus 
could be an important contributor to ADHD etiology.  
Attention deficit hyperactivity disorder (ADHD) is one of the most common neuropsychiatric disorders 
in children (seen in 3%–5% of school-age children) (1) and adults (2%–4%) (2). Twin and adoption 
studies have shown high heritability of ADHD, with estimates averaging 76% (3). The etiology of ADHD 
is complex, with contributions from both genes and environmental factors. Until recently, research on 
the genetics of ADHD has focused mainly on common genetic variants in candidate gene studies. The 
effect sizes of most associated genetic variants identified have been small (4, 5). The few genome-wide 
association studies (GWAS) performed so far have been too underpowered to observe genome-wide 
significant associations (6–11), which fits well with the view of ADHD as a polygenic, multifactorial 
disorder, to which many common DNA variants (and environmental factors) of small effect contribute.  
In contrast to this common disease-common variant hypothesis, rare genetic variants of moderate to 
large effect size have been found in a proportion of case subjects with other psychiatric disorders, such 
as schizophrenia and autism (12). So far, most such variants have been chromosomal aberrations and 
copy number variants (CNVs), deletions and duplications that encompass relatively large genomic 
segments spanning 1 kb to several megabases in size. Depending on their location, CNVs can influence 
gene expression through gene dosage effects or can directly influence protein function by excising or 
duplicating functional domains.  
In ADHD, large, rare chromosomal aberrations have been reported to increase the risk for 
ADHD—for example, through the 22q11 deletion syndrome (40%–45% of patients with this syndrome 
have ADHD) [13]—as have rare chromosomal alterations, including a translocation involving SLC9A9 
cosegregating with ADHD in an extended pedigree (14). The first published genome-wide analysis of 
CNVs in ADHD, which studied 335 ADHD child-parent trios and 2,026 healthy comparison subjects, 
failed to identify significant evidence for a higher rate of CNVs in patients (15). The study did, however, 
describe a number of the rare CNVs identified in ADHD patients, which spanned some intriguing 
candidate genes. A relatively large number of the CNVs occurred at loci that had previously been impli-
cated in other disorders, especially autism, schizophrenia, and Tourette’s syndrome. A second CNV 
study analyzed 99 ADHD patients (16) and identified a duplication of the neuropeptide Y gene (NPY) 
cosegregating with disease in an extended pedigree. A recent genome-wide study of CNVs in ADHD 
(17), in which 366 children with ADHD and 1,047 comparison subjects were analyzed, found evidence 
for an overall increased burden of large, rare CNVs in the ADHD patients, which were also significantly 
enriched at loci that had previously been implicated in autism and schizophrenia. Moreover, 
locus-specific analysis revealed significant evidence that duplications at 16p13.11 were associated with 
ADHD, a finding that was replicated in an additional 825 patients and 35,243 comparison subjects. The 
most recent study (18) investigated 248 children with ADHD and their parents and observed de novo 
CNVs in 1.7% of the children and inherited CNVs in genes previously linked to ADHD or other 
neurodevelopmental disorders in 8%.  
In this study, we followed up on these findings by performing a genome-wide analysis of CNVs in 896 
children with ADHD and 2,455 unrelated comparison subjects collected as part of the IMAGE II 
Consortium genome-wide association study (8), which represents the largest collection of ADHD cases 
studied to date.  
method  
Participants  
The 896 case subjects investigated in this study consisted of 1) samples collected by a subset of the 
International Multicenter ADHD Genetics (IMAGE) Project sites but not included in the IMAGE GWAS 
(7) and 2) samples collected at additional sites in the United Kingdom, Ireland, Germany, Switzerland, 
the Netherlands, and the United States and were assessed in a manner similar to that of the IMAGE 
samples. Case subjects were of European origin. At the collection sites, patients had been identified 
mainly through outpatient clinics, met DSM-IV criteria for ADHD, had been referred for assessment of 
hyperactive, disruptive, or disorganized behavior, and had been clinically diagnosed as having ADHD 
(or hyperkinetic disorder, the most closely equivalent category in the ICD-10 nomenclature used by 
some of the clinics) using semistructured interviews with parents. All sites excluded subjects with an IQ 
below 70. The characteristics of the full case sample have been described in detail elsewhere (8); the 
characteristics of the sample included in the final analysis of the present study are summarized in 
Table S1 in the online data supplement that accompanies the online edition of this article. 
Twenty-three cases overlap with a recent CNV analysis by Williams et al. (17); 99 cases overlap with 
another CNV analysis using array comparative genomic hybridization technology (16). Results from 
these overlapping cases are clearly marked in Table S4 in the data supplement. For 600 cases, 
additional data on ADHD subtype and severity as well as presence of comorbid oppositional defiant 
disorder or conduct disorder were available. All case data were collected with the informed consent of 
parents and with the approval of each site’s institutional review board or ethical committee.  
The comparison samples (2,455 population subjects of European ancestry) were collected for a GWAS 
of schizophrenia and have been described elsewhere (19). Briefly, the comparison subjects were 
drawn from a nationally representative U.S. survey panel ascertained via random digit dialing. Subjects 
were screened for psychosis and bipolar disorder but not for ADHD. A blood sample was collected via 
phlebotomy services. Comparison subjects gave written consent for their biological materials to be 
used for medical research at the discretion of the National Institute of Mental Health.  
Replication analysis was performed for the most frequent finding on chromosome 15q13. Replication 
samples included those from the recently published CNV study from Cardiff, U.K., excluding the 23 
ADHD cases that overlap with the IMAGE II discovery sample (296 DSM-IV ADHD case subjects with IQ 
>70 and 1,047 comparison subjects genotyped on Illumina Human660W-Quad BeadChip [for the case 
subjects] or HumanHap550 BeadChip [for the comparison subjects]) (17); from the PUWMa 
(Pfizer-funded study from UCLA, Washington University, and Massachusetts General Hospital) sample 
of 692 DSM-IV ADHD case subjects and 1,101 comparison subjects genotyped on the Illumina 1M 
BeadChip as described elsewhere (9); from a Canadian study that included 247 DSM-IV ADHD case 
subjects and 2,357 comparison subjects genotyped on the Affymetrix 6.0 array (18); and from an 
unpublished sample that included 1,013 DSM-IV ADHD case subjects and 4,105 comparison children 
genotyped on the Illumina Infinium HumanHap550K BeadChip at Children’s Hospital of Philadelphia. In 
the latter study, ADHD case subjects of Northern European descent (ages 6–18) were recruited from 
pediatric and behavioral health clinics in the Philadelphia area. Exclusionary criteria included 
prematurity (<36 weeks), mental retardation, major medical or neurological disorders, pervasive 
developmental disorder, psychosis, and major mood disorders.  
Statistical Analysis of Rare CNV Data  
Quality control for samples, the procedures for CNV calling, and quality control for the CNV calls are 
described in the online data supplement. The genome-wide burden of rare CNVs was assessed 
according to either the number of rare CNVs per sample or the average rare CNV size per sample. 
Gene-centric burden analysis was performed by limiting the analysis to rare CNVs that overlapped with 
the list of genes (defined according to +/– 50 kb of the largest transcript) present in National Center for 
Biotechnology Information Build 36.1-hg18 (http://pngu.mgh.harvard. 
edu/~purcell/plink/res.shtml#glist). In accordance with other studies, the significance of the burden 
comparisons was assessed via permutation (10,000 permutations, one-sided test) using PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink). Analyses were performed for all large, rare CNVs as 
well as by stratification according to CNV type (deletion or duplication) and size (>100 kb or >500 kb). 
Differences in the rates at which CNVs were called in males or females were assessed separately in 
case and comparison subjects using PLINK, with significance assessed via permutation (10,000 
permutations, two-sided test).  
To perform locus-specific tests of association, we first defined test regions according to the genomic 
boundaries for each CNV identified in the entire sample. Where multiple CNVs identified in different 
samples overlapped, they were merged to create a single locus that encompassed all overlapping 
CNVs. PLINK was then used to determine the number of CNVs present within each test region in case 
and comparison subjects. Locus-specific tests of association were made using PLINK, again with the 
significance being assessed via permutation (10,000 permutations, one-sided test).  
To assess whether the CNVs identified in our ADHD cohort were significantly enriched for loci 
previously implicated in schizophrenia or autism, we first defined the genomic coordinates for a list of 
single genes and genomic regions containing contiguous sets of genes that had previously been 
reported to harbor CNVs associated with a greater risk of autism (20) or schizophrenia (21–25). We 
then counted the number of CNVs larger than 100 kb in the case and comparison subjects that 
occurred within, or completely or partially overlapped, each locus. We also tested the overall 
significance of case-control comparisons for the total burden of CNVs at these loci using logistic 
regression analysis. To allow for the possibility that any significant overlap was caused by differences in 
the size of CNVs in the case and comparison subjects, we included CNV size as an independent 
variable.  
Validation of a Rare CNV on 15q13.3  
A total of 41 subjects were included in the validation study using quantitative real-time polymerase 
chain reaction analysis, including eight ADHD 15q13.3 duplication carriers (ADHD carriers) and their 
family members, eight randomly selected ADHD subjects without duplications (ADHD noncarriers), six 
comparison subjects with the duplication (control carriers), and four random comparison subjects 
(non-ADHD). The characteristics of each subject are summarized in Table S2 in the online data supple-
ment, and procedures are explained in Table S3.  
Replication of Duplications at 15q13.3  
The eight duplications identified in the ADHD patient sample at 15q13.3 spanned a consensus region 
of approximately 420 kb that was clearly defined by two segmental duplications 
(chr15:29,811,982–30,232,981, National Center for Biotechnology Information Build 36.1-hg18). From 
each replication cohort, we selected all duplications in the case and comparison subjects that spanned 
the 15q13.3 consensus region by at least 60%. Tests of association were then performed for each 
replication sample by Fisher’s exact test and for meta-analysis by logistic regression with sample site 
included as an independent variable. The Bres-low-Day test was used to test for heterogeneity 
between replication samples.  
Results  
A total of 732 ADHD cases passed quality control; 84% of subjects were male, and the mean age was 
10.4 years. Most had combined-type ADHD (81%), and the remainder had primarily inattentive (14%) 
or primarily hyperactive-impulsive ADHD (5%). In the subsample for which information on comorbid 
disorders was available, 18% had comorbid conduct disorder and 47% had comorbid oppositional 
defiant disorder. A detailed breakdown by site has been described (8) and is summarized in Table S1 in 
the online data supplement. After exclusion of common (minor allele frequency >0.01) CNVs, all 
association analyses were based on 1,562 rare CNVs larger than 100 kb (460 in case subjects and 1,102 
in comparison subjects; see Table S4 in the online data supplement). There was no significant 
difference in the rate at which CNVs >100 kb were called in males compared with females in either 
case or comparison subjects (data not presented).  
We observed a significant excess of rare CNVs >100 kb in our ADHD case subjects relative to 
comparison subjects, with a rate 1.15 times higher and a proportion of subjects carrying at least one 
rare CNV >100 kb 1.13 times higher (Table 1). There was no significant evidence to suggest that the 
rare CNVs identified in the ADHD cases were on average longer than those identified in the 
comparison subjects, a finding in line with that of a previous study using a different data set (17). 
Limiting our analysis to the largest CNVs suggested that the higher rate in ADHD cases was strongest 
for rare CNVs >500 kb (1.28 times higher in the ADHD cases, p=0.032; Table 1). The rate of rare CNVs 
>500 kb observed in ADHD cases was 12.2%, which is in accordance with the rate of 12.5% reported in 
the previous study using analogous methodology and a different data set (17). While there was a 
difference in the gender distribution between the ADHD cases and the population-based comparison 
sample (which was 48% male), there was no significant difference in the rate at which CNVs >100 kb 
were called in males compared with females in either case or comparison subjects (data not 
presented). When we restricted the analysis to CNVs >100 kb that spanned genes, we found a 
significantly greater burden of such CNVs in case subjects, which was strongest for duplications (Table 
1). There was no evidence of a greater burden of non-gene-centric CNVs >100 kb (minimum p=0.11; 
data not presented). As over 90% of CNVs >500 kb spanned at least one gene, the gene-centric burden 
analysis was limited to CNVs >100 kb.  
The 1,562 CNVs included in this study segregated into 912 independent loci (see Table S5 in the 
online data supplement). Genome-wide locus-specific analysis identified one region 
(chr15:28,231,568–30,571,466) that was nominally associated with ADHD (p=0.012), although this 
finding did not survive correction for genome-wide testing (p=0.79). Nevertheless, post hoc analysis of 
this locus revealed that the association was primarily contributed to by eight duplications in 732 ADHD 
cases, compared with six in the 2,010 comparison subjects (p=0.016 uncorrected), all of which spanned 
a consensus region of approximately 420 kb (chr15:29,811,982–30,232,981), defined by two segmental 
duplications (Figure 1). Validation of the CNV using a different genotyping method confirmed the 
presence of the variant in the ADHD cases and showed that it was inherited in all families for which 
both parents were available for testing (see Figure S1 in the online data supplement). While post hoc 
analyses failed to reveal any significant evidence that overall CNV carriership was associated with 
ADHD subtype, ADHD symptom dimension, or presence of oppositional defiant disorder, we did 
observe a nominally significant association (p=0.03 uncorrected) between conduct disorder and 
carriers of 15q13.3 duplications.  
We attempted to replicate the observation of an excess of duplications at 15q13.3 by studying an 
additional 2,242 ADHD case subjects and 8,552 comparison subjects in four independent samples of 
European Caucasian descent from the United States, the United Kingdom, and Canada (Table 2). 
Duplications spanning chr15:29,811,982–30,232,981 were found in case and comparison subjects from 
all samples (Figure 1), and they were indeed enriched in the ADHD patients across the replication 
samples (p=0.00275; Table 2). Combined analysis of all samples investigated (2,966 cases, 10,556 
comparison subjects) produced highly significant evidence that duplications at 15q13.3 are associated 
with ADHD (p=0.000178; odds ratio=2.22, 95% confidence interval=1.46–3.38).  
It was previously reported that CNVs identified in ADHD cases are enriched at loci that harbor CNVs 
associated with schizophrenia and autism (17). In the present study, we observed that 18 of 460 (3.9%) 
CNVs >100 kb identified in the case subjects overlapped with one of the 32 loci previously implicated in 
autism (20), compared with only 20 of 1,102 (1.8%) of the CNVs identified in comparison subjects 
(p=0.009; Table 3), representing a rate 2.16 times greater in case subjects relative to comparison 
subjects. We also observed that ADHD case subjects had a 1.49-fold excess of CNVs located at the 
eight loci previously implicated in schizophrenia relative to comparison subjects (5.4% compared with 
3.6%, p=0.03; Table 3). The lists of regions previously implicated in autism and schizophrenia are not 
independent of each other (they have five regions in common).  
Discussion  
Until recently, the common disease-common variant hypothesis has been used to explain the 
occurrence of most cases of psychiatric disorders. Recent studies showing a higher frequency of rare 
CNVs in psychiatric patients have challenged this view. Such rare CNVs have also been described in 
ADHD patients (15, 16, 18) and have been  
a 
Segmental duplications are labeled using the nomenclature defined by Szafranski et al. (26). 
FISH=fluorescent in situ hybridization.  
found to be enriched in this population (17). Our results in this study, a CNV analysis in the largest 
clinical sample hitherto investigated, support the findings of the previous study (17) reporting an 
increased burden of rare CNVs in ADHD patients. Whereas the latter study investigated only CNVs 
larger than 500 kb (showing enrichment in both deletions and duplications in the patients), we show 
here that an increased burden is also observed when CNVs down to 100 kb in size are considered.  
While most CNVs occurred only in single patients in our study, there was some overlap with the 
findings from the earlier CNV studies in ADHD (15–18), and some CNVs have been linked to ADHD in 
other ways (see Table S6 in the online data supplement). These CNVs mark genes that might be of 
particular relevance to ADHD and would make good candidates for further study.  
As also noted in earlier CNV studies in ADHD (15–17), we found significant evidence that CNV regions 
in ADHD patients overlapped with loci implicated by CNVs in autism and schizophrenia. Although 
schizophrenia and ADHD do not typically co-occur, ADHD and autism cooccur in patients more often 
than would be expected by chance, and they share heritability (27). The overlap in CNV loci among 
disorders suggests pleiotropy of genes predisposing to psychiatric disorders (28–31). Additional factors 
seem to be necessary to explain the specificity of a clinical phenotype. On the other hand, pleiotropy 
might also imply that the clinical classification tools for psychiatric disorders do not match the 
biological underpinnings of such disorders (28).  
In this study, we were also able to perform a regional analysis testing each locus carrying a CNV for 
association with ADHD. Despite earlier identification of ADHD case subjects carrying duplications at 
16p13 (17), in this sample there was no evidence for association between duplications at this locus and 
ADHD (two CNVs were found in case subjects, six in comparison subjects). However, we did identify 
significant associations of duplications at 15q13.3 with ADHD. Notably, we replicated this observation 
in a total of 2,242 independent ADHD cases and 8,552 comparison subjects from four different sites, 
including the study by Stergiakouli et al. (32). Duplications were identified at 15q13.3 in all studies and 
using all different platforms for CNV detection used, with odds ratios  
 
 
ranging from 0.91 to 3.99. Specifically, our data implicate duplications spanning a region of 
approximately 420 kb (chr15:29,811,982–30,232,981), which is flanked by two segmental duplications. 
However, as with all CNV analyses of single-nucleotide polymorphism (SNP) array data, our study had 
limited resolution to establish the nature of potentially complex rearrangements at this locus; 
therefore, we cannot exclude the possibility that some of the duplications identified at 15q13 are of a 
more complex nature. The presence of the 15q13.3 duplication also seemed to modulate the ADHD 
phenotype, as carriers had a higher lifetime rate of comorbid conduct disorder.  
Rare CNVs in this locus (deletions and duplications) have previously been implicated in several 
psychiatric disorders (e.g., autism, schizophrenia, intellectual disability), as well as nonpsychiatric 
conditions, such as epilepsy (33), albeit with reduced penetrance. The duplicated region contains a 
plausible candidate gene for ADHD, CHRNA7 (Mendelian Inheritance in Man code *118511), which en-
codes the a7 subunit of the neuronal nicotinic acetylcholine receptor, a homo-oligomeric ion channel 
involved in calcium signaling in the brain. The a7 nicotinic acetylcholine receptor participates in an 
ADHD-relevant pathway by mediating dopamine release (34). Dopamine dysregulation is strongly 
implicated in ADHD; in fact, a7 receptor agonists show modest efficacy for the treatment of ADHD 
(35). Two candidate gene studies of microsatellite markers and a SNP in and near this gene in ADHD 
have been negative (36, 37). However, a recent study implicates the receptor in the response to stress 
and shows that maternal genotype has a strong effect on offspring phenotype (38). This might suggest 
that this gene is a particularly interesting candidate for parent-of-origin and gene-environment 
interaction studies in ADHD.  
Do our findings imply that ADHD behaves as a mono-genic disease in the patients carrying CNVs? 
This study does not provide evidence that any of the rare CNVs identified in ADHD behave as highly 
penetrant variants, as overlap is routinely observed in findings between patients and comparison 
subjects. From this, we can conclude that these CNVs are neither necessary nor sufficient to cause 
ADHD. This is consistent with other studies of rare CNVs segregating in extended pedigrees, which did 
not report perfect cosegregation of risk variants with ADHD (16, 39) or autism (40). Therefore, while 
we accept that particularly for de novo variants we cannot exclude a high penetrance, we expect that 
most rare CNVs implicated in this and other studies are moderate risk factors for ADHD that interact 
with other DNA risk variants or environmental factors to cause the disorder.  
Our study has both strengths and weaknesses. Clearly, the study’s large sample size is an important 
strength, as is the availability of several replication cohorts. The potential weakness of using two 
different genotyping platforms for case and comparison subjects has been addressed by concentrating 
only on SNPs represented on both arrays, by strict quality control, and by analysis of only large, rare 
CNVs, which, in accordance with previous findings (17, 21), can be reliably called. Unfortunately, we 
could not assess the inheritance of most of our rare CNVs. Finally, our sample is not well suited for 
studying additional phenotypic variation, given the limited phenotypic range caused by the fact that 
most case subjects suffered from the most severe, combined form of ADHD. Even larger studies with 
more phenotypic variability might be necessary to investigate the effects of CNVs on the ADHD 
subtypes and correlates.  
In conclusion, our study provides further evidence for a role of large, rare CNVs in ADHD. The 
replicated association between ADHD and duplications on chromosome 15q13.3, increasing ADHD risk 
with an odds ratio of 2.22, is one of the strongest risk factors for ADHD identified thus far and, with a 
frequency >0.6% in the population, could be an important contributor to ADHD etiology.  
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